Prime assembly, a gene-editing method, was published in Nature on 16 September 2026. The study came from the Gene Therapy Programme at Boston Children's Hospital; the first author is Sébastien Levesque, and the corresponding author is Daniel E. Bauer. The article is titled "Targeted genomic integration and rearrangement using prime assembly" (DOI: 10.1038/s41586-026-11024-2).
In recent weeks, the method has been circulating on social media under the headline "new method corrects multiple mutations at once." This headline is not entirely wrong, but it does not fully explain what was done. Below, we set out what the article itself says, which parts are interpretation, and what stage things are at today, keeping these separate.
What is prime assembly?
Most gene-editing tools in use today make small changes: altering a single letter, or adding or removing a few letters. When larger segments need to be inserted, both strands of the DNA are usually cut and the cell's repair machinery is relied upon. This route carries two problems: a double-strand break is damaging to the cell, and this repair pathway works mainly in dividing cells.
Prime assembly is built on prime editing (a method that has been known for some time). It writes short DNA "flaps," one for each strand, at a chosen point in the genome. These flaps capture DNA segments whose ends match them, and the segment becomes permanently inserted at that point. The three features stated in the article's abstract are as follows:
- It allows single-stranded or double-stranded DNA segments to be inserted at a chosen point in an RNA-programmable manner.
- It works to a similar extent in dividing and non-dividing cells — this is what distinguishes it from the classical repair pathway (homology-directed repair).
- It does not require a double-stranded DNA template, a nuclease-induced double-strand break, or cell-cycle progression.
What does "multiple mutations at once" mean?
This distinction matters. What is meant here is not the simultaneous correction of separate mutations at different points in the genome. What is meant is this: the method can replace an entire segment of a gene — for example, an exon — with a rewritten version. Whatever mutation exists within that segment is removed by the same procedure.
In practical terms, this means the following: most gene-directed therapies today are mutation-specific. For two children carrying different mutations in the same gene, two separate designs are usually required, which means children with a rare variant end up at the back of the queue for treatment development. A method that can replace an entire exon could cover different mutations in the same gene with a single design. In most neurogenetic disorders — where each family carries a different variant — this distinction has considerable practical value.
In the article's abstract, this use is referred to as "targeted exon recoding." The phrase "universal gene therapy," however, is a framing used by news reports, not by the researchers.
What was done in the study?
According to the article's abstract, prime assembly was used for three separate tasks:
- Exon recoding — replacing a segment of a gene with a rewritten version.
- Transgene insertion — placing an external gene segment at a chosen point.
- Megabase-scale rearrangement — rearranging very large portions of the genome.
Some of this work, as stated in the abstract, was carried out in primary human cells and at therapeutically relevant sites. Which genes were targeted and the efficiency rates obtained are given in the full text of the article; we were unable to access the full text while preparing this piece, so we are not giving gene names or percentages here.
What stage is it at today?
This point needs to be clear:
- The study is a laboratory study at the cell level. The published abstract does not report any animal study or patient application.
- No disease has been treated. There is no clinical trial under way for any disease.
- The main obstacle noted by the research team itself is delivery: work is still under way on getting the method's components to the relevant cells within the body. The team names blood stem cells as its first target.
- The team also states that mechanistic work will continue in order to improve efficiency and precision.
Between a method working in the laboratory and it becoming applicable to a child lies a path measured in years, including safety studies and regulatory steps. We have described these steps for gene-directed therapies, and how long each one takes, on the Genetic Therapies — Basic Concepts page.
In terms of neurogenetic disorders
Two features of the method are worth noting with respect to the disorders we follow.
First, that it also works in non-dividing cells. The nervous system largely consists of non-dividing cells; methods requiring dividing cells are inherently limited in this tissue. The article's abstract does not mention nerve cells — this is an inference explaining why the feature is of interest, not a finding of the study itself.
Second, as described above, that a single design can cover many mutations in the same gene. In a significant proportion of diagnoses made through whole-exome or whole-genome sequencing, the variant is specific to that family; the mutation-specific treatment development model does not work for these children. An approach based on replacing a segment carries the possibility of bringing different variants in the same gene together in a shared solution.
Both notes are possibilities, not outcomes. This article has been written so that families can follow what the method is and what it is not.
A note for families
This is a research development; it is not a treatment recommendation or an announcement of access to treatment. Whatever your child's diagnosis, this publication does not require any change to your current follow-up and treatment plan. Continue your current medication, rehabilitation and follow-up programme; decisions to change anything are made together with the physician following your child.
On social media, developments of this kind are often presented as being at a more advanced stage than they actually are. The publication of a method in Nature does not mean that method can be used in patients. Our association will continue to follow this study and will share it with families when it reaches a clinical stage.
Sources: Levesque S, Kawashima N, Hwang GH, Zeng J, Toskov V, Barry T, Mannherz W, Homfeldt L, Becerra B, Schoonenberg VAC, Pinello L, Agarwal S, Bauer DE. "Targeted genomic integration and rearrangement using prime assembly." Nature, 16 September 2026. PMID 42749803 — DOI: 10.1038/s41586-026-11024-2 (citation and abstract taken from PubMed; the full text could not be accessed) · Boston Children's Hospital press release, EurekAlert, 16 September 2026 — the limitations regarding delivery and efficiency, and the blood stem cell target, are based on this release. The assessment of what the method's working in non-dividing cells means for the nervous system, and of a single design's ability to cover different variants, is not a finding reported in the sources but an interpretation offered in this article.
